Retroviral transfer of human cytochrome P450 genes for oxazaphosphorine- based cancer gene therapy

Cancer Research

Volumn 58, Issue 19, 1998, Pages 4391-4401

  Jounaidi, Youssef ^a   Hecht, Jodi E D ^a   Waxman, David J ^a  

^a USA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYTOCHROME P450; IFOSFAMIDE; OXAZAPHOSPHORINE DERIVATIVE;

ARTICLE; CANCER; CYTOTOXICITY; DRUG ACTIVATION; DRUG DISTRIBUTION; GENE THERAPY; GENE TRANSFER; GLIOSARCOMA; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; CLONE CELLS; CYCLOPHOSPHAMIDE; CYTOCHROME P-450 CYP2B1; CYTOCHROME P-450 ENZYME SYSTEM; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; GLIOSARCOMA; HUMANS; IFOSFAMIDE; MALE; MICE; MICE, INBRED ICR; MICE, SCID; RETROVIRIDAE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0032190113     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (70)

1. Kivisto, K. T., Kroemer, H. K., and Eichelbaum, M. The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions. Br. J. Clin. Pharmacol., 40: 523-530, 1995.
2. LeBlanc, G. A., and Waxman, D. J. Interaction of anticancer drugs with hepatic monooxygenase enzymes. Drug Metab. Rev., 20: 395-439, 1989.
3. Moolten, F. L. Drug sensitivity ("suicide") genes for selective cancer chemotherapy. Cancer Gene Ther., 1: 279-287, 1994.
4. Deonarain, M. P., Spooner, R. A., and Epenetos, A. A. Genetic delivery of enzymes for cancer therapy. Gene Ther., 2: 235-244, 1995.
5. Pope, I. M., Poston, G. J., and Kinsella, A. R. The role of the bystander effect in suicide gene therapy. Eur. J. Cancer, 33: 1005-1016, 1997.
6. Faulds, D., and Heel, R. C. Ganciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infections. Drugs, 39: 597-638, 1990.
7. Moolten, F. L., and Wells, J. M. Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors. J. Natl. Cancer Inst. (Bethesda), 82: 297-300, 1990.
8. Ezzeddine, Z. D., Martuza, R. L., Platika, D., Short, M. P., Malick, A., Choi, B., and Breakefield, X. O. Selective killing of glioma cells in culture and in vivo by retrovirus transfer of the herpes simplex virus thymidine kinase gene. New Biol., 3: 608-614, 1991.
9. Mullen, C. A., Kilstrup, M., and Blaese, R. M. Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system. Proc. Natl. Acad. Sci. USA, 89: 33-37, 1992.
10. Huber, B. E., Austin, E. A., Good, S. S., Knick, V. C., Tibbels, S., and Richards, C. A. In vivo antitumor activity of 5-fluorocytosine on human colorectal carcinoma cells genetically modified to express cytosine deaminase. Cancer Res., 53: 4619-4626, 1993.
11. Freeman, S. M., Abboud, C. N., Whartenby, K. A., Packman, C. H., Koeplin, D. S., Moolten, F. L., and Abraham, G. N. The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res., 53: 5274-5283, 1993.
12. Chen, C. Y., Chang, Y. N., Ryan, P., Linscott, M., McGarrity, G. J., and Chiang, Y. L. Effect of herpes simplex virus thymidine kinase expression levels on ganciclovir-mediated cytotoxicity and the "bystander effect." Hum. Gene Ther., 6: 1467-1476, 1995.
13. Gagandeep, S., Brew, R., Green, B., Christmas, S. E., Klatzmann, D., Poston, G. J., and Kinsella, A. R. Prodrug-activated gene therapy: involvement of an immunological component in the "bystander effect." Cancer Gene Ther., 3: 83-88, 1996.
14. Link, C. J., Jr., Moorman, D., Seregina, T., Levy, J. P., and Schabold, K. J. A Phase I trial of in vivo gene therapy with the herpes simplex thymidine kinase/ganciclovir system for the treatment of refractory or recurrent ovarian cancer. Hum. Gene Ther., 7: 1161-1179, 1996.
15. Eck, S. L., Alavi, J. B., Alavi, A., Davis, A., Hackney, D., Judy, K., Mollman, J., Phillips, P. C., Wheeldon, E. B., and Wilson, J. M. Treatment of advanced CNS malignancies with the recombinant adenovirus H5.010RSVTK: a Phase I trial. Hum. Gene Ther., 7: 1465-1482, 1996.
16. Roth, J. A., and Cristiano, R. J. Gene therapy for cancer: what have we done and where are we going? J. Natl. Cancer Inst. (Bethesda), 89: 21-39, 1997.
17. Mesnil, M., Piccoli, C., Tiraby, G., Willecke, K., and Yamasaki, H. Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins. Proc. Natl. Acad. Sci. USA, 93: 1831-1835, 1996.
18. Sladek, N. E. Metabolism of oxazaphosphorines. Pharmacol. Ther., 37: 301-355, 1988.
19. Clarke, L., and Waxman, D. J. Oxidative metabolism of cyclophosphamide: identification of the hepatic monooxygenase catalysts of drug activation. Cancer Res., 49: 2344-2350, 1989.
20. Davidoff, A. N., and Mendelow, B. V. Cell-cycle disruptions and apoptosis induced by the cyclophosphamide derivative mafosfamide. Exp. Hematol., 21: 922-927, 1993.
21. Lee, J. H., Park, J. H., and Yang, M. H. The effect of cyclophosphamide on Fas-mediated apoptosis. J. Korean Med. Sci., 12: 185-189, 1997.
22. Kaijser, G. P., Korst, A., Beijnen, J. H., Bult, A., and Underberg, W. J. The analysis of ifosfamide and its metabolites (review). Anticancer Res., 13: 1311-1324, 1993.
23. Weber, G. F., and Waxman, D. J. Activation of the anti-cancer drug ifosphamide by rat liver microsomal P450 enzymes. Biochem. Pharmacol., 45: 1685-1694, 1993.
24. Chang, T. K. H., Weber, G. F., Crespi, C. L., and Waxman, D. J. Differential activation of cyclophosphamide and ifosphamide by cytochromes P450 2B and 3A in human liver microsomes. Cancer Res., 53: 5629-5637, 1993.
25. Fleming, R. A. An overview of cyclophosphamide and ifosfamide pharmacology. Pharmacotherapy, 17 (Suppl.): 146S-154S, 1997.
26. Demetri, G. D. High-dose ifosfamide in the treatment of sarcomas of soft tissues and bone. Semin. Oncol., 23: 22-26, 1996.
27. Overmoyer, B. A. Ifosfamide in the treatment of breast cancer. Semin. Oncol., 23: 38-41, 1996.
28. Nelson, D. R., Koymans, L., Kamataki, T., Stegeman, J. J., Feyereisen, R., Waxman, D. J., Waterman, M. R., Gotoh, O., Coon, M. J., Estabrook, R. W., Gunsalus, I. C., and Nebert, D. W. Cytochrome P450 superfamily: update on new sequences, gene mapping, accession numbers, and nomenclature. Pharmacogenetics, 6: 1-42, 1996.
29. Chen, L., and Waxman, D. J. Intratumoral activation and enhanced chemotherapeutic effect of oxazaphosphorines following cytochrome P450 gene transfer: development of a combined chemotherapy/cancer gene therapy strategy. Cancer Res., 55: 581-589, 1995.
30. Wei, M. X., Tamiya, T., Chase, M., Boviatsis, E. J., Chang, T. K. H., Kowall, N. W., Hochberg, F. H., Waxman, D. J., Breakefield, X. O., and Chiocca, E. A. Experimental tumor therapy in mice using the cyclophosphamide-activating cytochrome P450 2B1 gene. Hum. Gene Ther., 5: 969-978, 1994.
31. Chen, L., Waxman, D. J., Chen, D., and Kufe, D. W. Sensitization of human breast cancer cells to cyclophosphamide and ifosfamide by transfer of a liver cytochrome P450 gene. Cancer Res., 56: 1331-1340, 1996.
32. Chase, M., Chung, R. Y., and Chiocca, E. A. An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy. Nat. Biotechnol., 16: 444-448, 1998.
33. Waxman, D. J., Chen, L., Hecht, J. E. D., and Jounaidi, Y. Cytochrome P450-based cancer gene therapy: recent advances and future prospects. Drug Metab. Rev., in press, 1998.
34. Walker, D., Flinois, J. P., Monkman, S. C., Beloc, C., Boddy, A. V., Cholerton, S., Daly, A. K., Lind, M. J., Pearson, A. D. J., Beaune, P. H., and Idle, J. R. Identification of the major human hepatic cytochrome P450 involved in activation and N-dechloroethylation of ifosfamide. Biochem. Pharmacol., 47: 1157-1163, 1994.
35. m catalysts of cyclophosphamide and ifosfamide activation. Pharmacogenetics, 7: 211-221, 1997.
36. Morgenstern, J. P., and Land, H. Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res., 18: 3587-3596, 1990.
37. Pear, W. S., Nolan, G. P., Scott, M. L., and Baltimore, D. Production of high-titer helper-free retroviruses by transient transfection. Proc. Natl. Acad. Sci. USA, 90: 8392-8396, 1993.
38. Chen, L., Yu, L. J., and Waxman, D. J. Potentiation of cytochrome P450/cyclophosphamide-based cancer gene therapy by coexpression of the P450 reductase gene. Cancer Res., 57: 4830-4837, 1997.
39. Goldstein, J. A., and de Morais, S. M. Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics, 4: 285-299, 1994.
40. Edwards, R. J., Singleton, A. M., Murray, B. P., Davies, D. S., and Boobis, A. R. Short synthetic peptides exploited for reliable and specific targeting of antibodies to the C-termini of cytochrome P450 enzymes. Biochem. Pharmacol., 49: 39-47, 1995.
41. Yasukochi, Y., and Masters, B. S. S. Some properties of a detergent-solubilized NADPH-cytochrome c (cytochrome P450) reductase purified by biospecific affinity chromatography. J. Biol. Chem., 251: 5337-5344, 1976.
42. Chirgwin, J. M., Przybyla, A. E., MacDonald, R. J., and Rutter, W. J. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry, 18: 5294-5299, 1979.
43. Paine-Murrieta, G. D., Taylor, C. W., Curtis, R. A., Lopez, M. H., Dorr, R. T., Johnson, C. S., Funk, C. Y., Thompson, F., and Hersh, E. M. Human tumor models in the severe combined immune deficient (scid) mouse. Cancer Chemother. Pharmacol., 40: 209-214, 1997.
44. Tapscott, S. J., Miller, A. D., Olson, J. M., Berger, M. S., Groudine, M., and Spence, A. M. Gene therapy of rat 9L gliosarcoma tumors by transduction with selectable genes does not require drug selection. Proc. Natl. Acad. Sci. USA, 91: 8185-8189, 1994.
45. Robbins, P. D., Tahara, H., and Ghivizzani, S. C. Viral vectors for gene therapy. Trends Biotechnol., 16: 35-40, 1998.
46. Kim, V. N., Mitrophanous, K., Kingsman, S. M., and Kingsman, A. J. Minimal requirement for a lentivirus vector based on human immunodeficiency virus type 1. J. Virol., 72: 811-816, 1998.
47. Nakanishi, M. Gene introduction into animal tissues. Crit. Rev. Ther. Drug Carrier Systems, 12: 263-310, 1995,
48. Pawelek, J. M., Low, K. B., and Bermudes, D. Tumor-targeted Salmonella as a novel anticancer vector. Cancer Res., 57: 4537-4544, 1997.
49. Hofmann, A., Nolan, G. P., and Blau, H. M. Rapid retroviral delivery of tetracycline-inducible genes in a single autoregulatory cassette. Proc. Natl. Acad. Sci. USA, 93: 5185-5190, 1996.
50. Massie, B., Couture, F., Lamoureux, L., Mosser, D. D., Guilbault, C., Jolicoeur, P., Belanger, F., and Langelier, Y. Inducible overexpression of a toxic protein by an adenovirus vector with a tetracycline-regulatable expression cassette. J. Virol., 72: 2289-2296, 1998.
51. Schneider, A., Schmalix, W. A., Siruguri, V., de Groene, E. M., Horbach, G. J., Kleingeist, B., Lang, D., Bocker, R., Belloc, C., Beaune, P., Greim, H., and Doehmer, J. Stable expression of human cytochrome P450 3A4 in conjunction with human NADPH-cytochrome P450 oxidoreductase in V79 Chinese hamster cells. Arch. Biochem. Biophys., 332: 295-304, 1996.
52. Yu, L., and Waxman, D. J. Role of cytochrome P450 in oxazaphosphorine metabolism. Deactivation via N-dechloroethylation and activation via 4-hydroxylation catalyzed by distinct subsets of rat liver cytochromes P450. Drug Metab. Dispos., 24: 1254-1262, 1996.
53. Patterson, A. V., Barham, H. M., Chinje, E. C, Adams, G. E., Harris, A. L., and Stratford, I. J. Importance of P450 reductase activity in determining sensitivity of breast tumour cells to the bioreductive drug, tirapazamine (SR 4233). Br. J. Cancer, 72: 1144-1150, 1995.
54. Workman, P., and Stratford, I. J. The experimental development of bioreductive drugs and their role in cancer therapy. Cancer Metastasis Rev., 12: 73-82, 1993.
55. O'Rourke, J. F., Dachs, G. U., Gleadle, J. M., Maxwell, P. H., Pugh, C. W., Stratford, I. J., Wood, S. M., and Ratcliffe, P. J. Hypoxia response elements. Oncol. Res., 9: 327-332, 1997.
56. Dachs, G. U., Patterson, A. V., Firth, J. D., Ratcliffe, P. J., Townsend, K. M., Stratford, I. J., and Harris, A. L. Targeting gene expression to hypoxic tumor cells. Nat. Med., 3: 515-520, 1997.
57. Brown, J. M., and Giaccia, A. J. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res., 58: 1408-1416, 1998.
58. Shimada, T., Yamazaki, H., Mimura, M., Inui, Y., and Guengerich, F. P. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther., 270: 414-423, 1994.
59. Furuya, H., Meyer, U. A., Gelboin, H. V., and Gonzalez, F. J. Polymerase chain reaction-directed identification, cloning, and quantification of human CYP2C18 mRNA. Mol. Pharmacol., 40: 375-382, 1991.
60. Ren, S., Yang, J. S., Kalhorn, T. F., and Slattery, J. T. Oxidation of cyclophosphamide to 4-hydroxycyclophosphamide and deschloroethylcyclophosphamide in human liver microsomes. Cancer Res., 57: 4229-4235, 1997.
61. Goldstein, J. A., Faletto, M. B., Romkes-Sparks, M., Sullivan, T., Kitareewan, S., Raucy, J. L., Lasker, J. M., and Ghanayem, B. I. Evidence that CYP2C19 is the major (S)-mephenytoin 4′-hydroxylase in humans. Biochemistry, 33: 1743-1752, 1994.
62. Faber, O. K., Mouridsen, H. T., and Skovsted, L. The effect of chloramphenicol and sulphaphenazole on the biotransformation of cyclophosphamide in man. Br. J. Clin. Pharmacol., 2: 281-285, 1975.
63. Heise, C., Sampson-Johannes, A., Williams, A., McCormick, F., Von Hoff, D. D., and Kirn, D. H. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat. Med., 3: 639-645, 1997.
64. Feng, M., Jackson, W. H., Jr., Goldman, C. K., Rancourt, C., Wang, M., Dusing, S. K., Siegal, G., and Curiel, D. T. Stable in vivo gene transduction via a novel adenoviral/retroviral chimeric vector. Nat. Biotechnol., 15: 866-870, 1997.
65. Chen, X., Li, Y., Xiong, K., Aizicovici, S., Xie, Y., Zhu, Q., Sturtz, F., Shulok, J., Snodgrass, R., Wagner, T. E., and Platika, D. Cancer gene therapy by direct tumor injections of a nonviral T7 vector encoding a thymidine kinase gene. Hum. Gene Ther., 9: 729-736, 1998.
66. Morgan, R. A., Couture, L., Elroy-Stein, O., Ragheb, J., Moss, B., and Anderson, W. F. Retroviral vectors containing putative internal ribosome entry sites: development of a polycistronic gene transfer system and applications to human gene therapy. Nucleic Acids Res., 20: 1293-1299, 1992.
67. Fisher, C. W., Shet, M. S., and Estabrook, R. W. Construction of plasmids and expression in Escherichia coli of enzymatically active fusion proteins containing the heme-domain of a P450 linked to NADPH-P450 reductase. Methods Enzymol., 272: 15-25, 1996.
68. Gunzburg, W. H., Karle, P., Mrochen, S., Sparmann, G., Saller, R., Klein, D., Uckert, W., and Salmons, B. Regulated gene expression after retroviral vector-mediated delivery of cancer-relevant therapeutic genes. Rec. Results Cancer Res., 144: 116-126, 1998.
69. Walther, W., and Stein, U. Cell type specific and inducible promoters for vectors in gene therapy as an approach for cell targeting. J. Mol. Med., 74: 379-392, 1996.
70. Schnierle, B. S., and Groner, B. Retroviral targeted delivery. Gene Ther., 3: 1069-1073, 1996.